Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
Nikolaou VA, Apalla Z, Carrera C, Fattore D, Sollena P, Riganti J, Segura S, Freites-Martinez A, Lallas K, Romano MC, Oikonomou C, Starace M, Dimopoulos MA, Kyrgidis A, Lazaridou E, Giavedoni P, Annunziata MC, Peris K, Echeverría M, Lopez-Tujillo E, Syrigos K, Papageorgiou C, Podlipnik S, Fabbrocini G, Torre AC, Kemanetzi C, Villa-Crespo L, Lallas A, Stratigos AJ, Sibaud V. Nikolaou VA, et al. Among authors: sibaud v. Br J Dermatol. 2022 Dec;187(6):962-969. doi: 10.1111/bjd.21781. Epub 2022 Sep 6. Br J Dermatol. 2022. PMID: 35861701
Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors.
Sollena P, Nikolaou V, Soupos N, Kotteas E, Voudouri D, Stratigos AJ, Fattore D, Annunziata MC, Orlandi A, Di Nardo L, Apalla Z, Deilhes F, Romano MC, Fabbrocini G, Sibaud V, Peris K; European Network for Cutaneous ADverse event of Oncologic drugs (ENCADO) group. Sollena P, et al. Among authors: sibaud v. Breast Cancer Res Treat. 2021 Jan;185(1):247-253. doi: 10.1007/s10549-020-05914-w. Epub 2020 Sep 10. Breast Cancer Res Treat. 2021. PMID: 32914354
Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group.
Nikolaou V, Sibaud V, Fattore D, Sollena P, Ortiz-Brugués A, Giacchero D, Romano MC, Riganti J, Lallas K, Peris K, Voudouri D, Lallas A, Fabbrocini G, Lazaridou E, Carrera C, Annunziata MC, Rossi E, Patri A, Rigopoulos D, Stratigos AJ, Apalla Z. Nikolaou V, et al. Among authors: sibaud v. J Am Acad Dermatol. 2021 May;84(5):1310-1320. doi: 10.1016/j.jaad.2020.08.137. Epub 2020 Dec 3. J Am Acad Dermatol. 2021. PMID: 33279646
Morphea-like changes in the setting of cancer immunotherapy.
De Simone C, Mannino M, Sollena P, Deilhes F, Sibaud V, Peris K. De Simone C, et al. Among authors: sibaud v. J Eur Acad Dermatol Venereol. 2021 Oct;35(10):e684-e685. doi: 10.1111/jdv.17388. Epub 2021 Jun 3. J Eur Acad Dermatol Venereol. 2021. PMID: 34013609 No abstract available.
European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force 'Dermatology for cancer patients' position statement.
Apalla Z, Nikolaou V, Fattore D, Fabbrocini G, Freites-Martinez A, Sollena P, Lacouture M, Kraehenbuehl L, Stratigos A, Peris K, Lazaridou E, Richert B, Vigarios E, Riganti J, Baroudjian B, Filoni A, Dodiuk-Gad R, Lebbé C, Sibaud V. Apalla Z, et al. Among authors: sibaud v. J Eur Acad Dermatol Venereol. 2022 Mar;36(3):332-350. doi: 10.1111/jdv.17855. Epub 2021 Dec 15. J Eur Acad Dermatol Venereol. 2022. PMID: 34910332
177 results